{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T19:09:34Z","timestamp":1773515374369,"version":"3.50.1"},"reference-count":89,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jbspin.2021.105309","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T11:52:24Z","timestamp":1637149944000},"page":"105309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Serotonin and systemic sclerosis. An emerging player in pathogenesis"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3738-3813","authenticated-orcid":false,"given":"Ioannis","family":"Sagonas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8027-3655","authenticated-orcid":false,"given":"Dimitrios","family":"Daoussis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2021.105309_bib0450","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/1744666X.2019.1614915","article-title":"Pathophysiology of systemic sclerosis: current understanding and new insights","volume":"15","author":"Cutolo","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jbspin.2021.105309_bib0455","doi-asserted-by":"crossref","first-page":"33","DOI":"10.31138\/mjr.30.1.33","article-title":"Treatment of systemic sclerosis-associated fibrotic manifestations: current options and future directions","volume":"30","author":"Daoussis","year":"2019","journal-title":"Mediterr J Rheumatol"},{"key":"10.1016\/j.jbspin.2021.105309_bib0460","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.semarthrit.2017.05.004","article-title":"The role of platelets in autoimmunity, vasculopathy, and fibrosis: implications for systemic sclerosis","volume":"47","author":"Ntelis","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2021.105309_bib0465","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11926-019-0815-z","article-title":"Platelets in systemic sclerosis: the missing link connecting vasculopathy, autoimmunity, and fibrosis?","volume":"21","author":"Ntelis","year":"2019","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jbspin.2021.105309_bib0470","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1177\/0269881117725915","article-title":"Serotonin and brain function: a tale of two receptors","volume":"31","author":"Carhart-Harris","year":"2017","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jbspin.2021.105309_bib0475","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1210\/en.2016-1839","article-title":"The diverse metabolic roles of peripheral serotonin","volume":"158","author":"Martin","year":"2017","journal-title":"Endocrinology"},{"key":"10.1016\/j.jbspin.2021.105309_bib0480","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1007\/s00018-007-7377-3","article-title":"Role of serotonin in the hepato-gastrointestinal tract: an old molecule for new perspectives","volume":"65","author":"Lesurtel","year":"2008","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jbspin.2021.105309_bib0485","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev-med-090710-133426","article-title":"Regulation of bone mass by serotonin: molecular biology and therapeutic implications","volume":"62","author":"Karsenty","year":"2011","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jbspin.2021.105309_bib0490","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/jbmr.2724","article-title":"Decreased serotonin levels and serotonin-mediated osteoblastic inhibitory signaling in patients with ankylosing spondylitis","volume":"31","author":"Klavdianou","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jbspin.2021.105309_bib0495","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nm.2098","article-title":"Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis","volume":"16","author":"Yadav","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.jbspin.2021.105309_bib0500","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.pharmthera.2011.03.008","article-title":"Serotonin receptors and heart valve disease\u00a0\u2013\u00a0It was meant 2B","volume":"132","author":"Hutcheson","year":"2011","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jbspin.2021.105309_bib0505","first-page":"1","article-title":"Pathological insight into 5-ht2b receptor activation in fibrosing interstitial lung diseases","volume":"22","author":"L\u00f6fdahl","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jbspin.2021.105309_bib0510","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.clim.2018.12.009","article-title":"Elevated kynurenine levels in diffuse cutaneous and anti-RNA polymerase III positive systemic sclerosis","volume":"199","author":"Corrado","year":"2019","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jbspin.2021.105309_bib0515","doi-asserted-by":"crossref","DOI":"10.1177\/2045894018759125","article-title":"The serotonin hypothesis in pulmonary hypertension revisited: targets for novel therapies (2017 Grover Conference Series)","volume":"8","author":"MacLean","year":"2018","journal-title":"Pulm Circ"},{"key":"10.1016\/j.jbspin.2021.105309_bib0520","series-title":"Membrane Receptors, Channels and Transporters in Pulmonary Circulation","first-page":"309","volume":"vol. 661","author":"MacLean","year":"2010"},{"key":"10.1016\/j.jbspin.2021.105309_bib0525","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1210\/er.2018-00283","article-title":"Emerging roles for serotonin in regulating metabolism: new implications for an ancient molecule","volume":"40","author":"Yabut","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.jbspin.2021.105309_bib0530","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nrendo.2009.51","article-title":"Fibrosis and carcinoid syndrome: from causation to future therapy","volume":"5","author":"Druce","year":"2009","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jbspin.2021.105309_bib0535","first-page":"65","article-title":"Carcinoid heart disease: pathophysiology, pathology, clinical manifestations, and management","volume":"146","author":"Jin","year":"2021","journal-title":"Cardiol"},{"key":"10.1016\/j.jbspin.2021.105309_bib0540","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000381930","article-title":"Carcinoid heart disease: from pathophysiology to treatment\u00a0\u2013\u00a0\u201cSomething in the way it moves.\u201d","volume":"101","author":"Grozinsky-Glasberg","year":"2015","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.jbspin.2021.105309_bib0545","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1136\/thx.2009.134353","article-title":"Increased expression of 5-hydroxytryptamine2A\/B receptors in idiopathic pulmonary fibrosis: a rationale for therapeutic intervention","volume":"65","author":"K\u00f6nigshoff","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.jbspin.2021.105309_bib0550","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1007\/s00018-018-2880-2","article-title":"Tryptophan metabolites kynurenine and serotonin regulate fibroblast activation and fibrosis","volume":"75","author":"Dolivo","year":"2018","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jbspin.2021.105309_bib0555","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1161\/01.CIR.0000159356.42064.48","article-title":"Long-term serotonin administration induces heart valve disease in rats","volume":"111","author":"Gustafsson","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jbspin.2021.105309_bib0560","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1161\/CIRCULATIONAHA.105.554667","article-title":"Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice","volume":"113","author":"Mekontso-Dessap","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jbspin.2021.105309_bib0565","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1183\/09031936.00126907","article-title":"Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice","volume":"32","author":"Fabre","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jbspin.2021.105309_bib0570","doi-asserted-by":"crossref","first-page":"106036","DOI":"10.1016\/j.intimp.2019.106036","article-title":"Serotonin receptors 5-HTR2A and 5-HTR2B are involved in cigarette smoke-induced airway inflammation, mucus hypersecretion and airway remodeling in mice","volume":"81","author":"Yang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jbspin.2021.105309_bib0575","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejphar.2017.08.014","article-title":"5-HT7 receptor antagonism (SB-269970) attenuates bleomycin-induced pulmonary fibrosis in rats via downregulating oxidative burden and inflammatory cascades and ameliorating collagen deposition: comparison to terguride","volume":"814","author":"Tawfik","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jbspin.2021.105309_bib0580","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2353\/ajpath.2006.050767","article-title":"A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis","volume":"169","author":"Ruddell","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jbspin.2021.105309_bib0585","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/liv.12110","article-title":"5-HT2A receptor antagonists inhibit hepatic stellate cell activation and facilitate apoptosis","volume":"33","author":"Kim","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.jbspin.2021.105309_bib0590","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/hep.30880","article-title":"Modulation of the tryptophan hydroxylase 1\/monoamine oxidase-A\/5-hydroxytryptamine\/5-hydroxytryptamine receptor 2A\/2B\/2C axis regulates biliary proliferation and liver fibrosis during cholestasis","volume":"71","author":"Kyritsi","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jbspin.2021.105309_bib0595","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1038\/nm.2490","article-title":"Stimulating healthy tissue regeneration by targeting the 5-HT 2B receptor in chronic liver disease","volume":"17","author":"Ebrahimkhani","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.jbspin.2021.105309_bib0600","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1084\/jem.20101629","article-title":"Platelet-derived serotonin links vascular disease and tissue fibrosis","volume":"208","author":"Dees","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.jbspin.2021.105309_bib0605","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1111\/1756-185X.13386","article-title":"5-HT 2 and 5-HT 2B antagonists attenuate pro-fibrotic phenotype in human adult dermal fibroblasts by blocking TGF-\u03b21 induced non-canonical signaling pathways including STAT3: implications for fibrotic diseases like scleroderma","volume":"21","author":"Chaturvedi","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105309_bib0610","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-15348-y","article-title":"Serotonin drives the acquisition of a pro-fibrotic and anti-inflammatory gene profile through the 5-HT7R-PKA signaling axis","volume":"7","author":"Dom\u00ednguez-Soto","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jbspin.2021.105309_bib0615","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/art.38288","article-title":"Association of interferon- and transforming growth factor \u03b2-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis","volume":"66","author":"Christmann","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2021.105309_bib0620","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar4598","article-title":"Chronic Toll-like receptor 4 stimulation in skin induces inflammation, macrophage activation, transforming growth factor beta signature gene expression, and fibrosis","volume":"16","author":"Stifano","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2021.105309_bib0625","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s10020-019-0126-x","article-title":"Role of 5-HT7 receptors in the immune system in health and disease","volume":"26","author":"Quintero-Villegas","year":"2020","journal-title":"Mol Med"},{"key":"10.1016\/j.jbspin.2021.105309_bib0630","doi-asserted-by":"crossref","DOI":"10.1002\/art.39817","article-title":"Platelets induce thymic stromal lymphopoietin production by endothelial cells: contribution to fibrosis in human systemic sclerosis","volume":"68","author":"Truchetet","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2021.105309_bib0635","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar2495","article-title":"A polymorphism in the human serotonin 5-HT2A receptor gene may protect against systemic sclerosis by reducing platelet aggregation","volume":"10","author":"Beretta","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2021.105309_bib0640","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/ar2606","article-title":"5HT2A polymorphism His452Tyr in a German Caucasian systemic sclerosis population","volume":"11","author":"Kirsten","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2021.105309_bib0645","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2133.1976.tb15534.x","article-title":"Hypersensitivity of scleroderma cutaneous vascular smooth muscle to 5-hydroxytryptamine","volume":"95","author":"Winkelmann","year":"1976","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jbspin.2021.105309_bib0650","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/BF00561375","article-title":"Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon","volume":"35","author":"Marasini","year":"1988","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jbspin.2021.105309_bib0655","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0167-5273(88)90238-0","article-title":"Plasma free and intraplatelet serotonin in patients with Raynaud's phenomenon","volume":"19","author":"Biondi","year":"1988","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jbspin.2021.105309_bib0660","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1346-8138.2000.tb02246.x","article-title":"Changes in plasma serotonin concentration and acceleration plethysmograms in patients with Raynaud's phenomenon after long-term treatment with a 5-HT2 receptor antagonist","volume":"27","author":"Igarashi","year":"2000","journal-title":"J Dermatol"},{"key":"10.1016\/j.jbspin.2021.105309_bib0665","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/jcp.42.7.716","article-title":"Abnormal platelet aggregation in patients with Raynaud's phenomenon","volume":"42","author":"Biondi","year":"1989","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jbspin.2021.105309_bib0670","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1042\/cs0860269","article-title":"Plasma levels of 5-hydroxytryptamine during sympathetic stimulation and in Raynaud's phenomenon","volume":"86","author":"Coffman","year":"1994","journal-title":"Clin Sci"},{"key":"10.1016\/j.jbspin.2021.105309_bib0675","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0002-9343(89)80148-2","article-title":"International study of ketanserin in Raynaud's phenomenon","volume":"87","author":"Coffman","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.jbspin.2021.105309_bib0680","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/bmj.289.6445.577","article-title":"Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders","volume":"289","author":"Roald","year":"1984","journal-title":"Br Med J"},{"key":"10.1016\/j.jbspin.2021.105309_bib0685","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1177\/000331978803900705","article-title":"Ketanserin in the treatment of progressive systemic sclerosis","volume":"39","author":"Altomare","year":"1988","journal-title":"Angiology"},{"key":"10.1016\/j.jbspin.2021.105309_bib0690","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1177\/000331978703800706","article-title":"Therapeutic efficacy of ketanserin, a selective antagonist of the serotonin (5-HT 2) receptors, in primary and secondary Raynaud's phenomenon","volume":"38","author":"Meloni","year":"1987","journal-title":"Angiology"},{"key":"10.1016\/j.jbspin.2021.105309_bib0695","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/art.1780270204","article-title":"Treatment of raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor","volume":"27","author":"Seibold","year":"1984","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2021.105309_bib0700","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2133.1989.tb07791.x","article-title":"Ketanserin in the treatment of systemic sclerosis: a double-blind controlled trial","volume":"120","author":"Ortonne","year":"1989","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jbspin.2021.105309_bib0705","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1097\/00005344-198409000-00037","article-title":"Ketanserin (5 HT2-Antagonist) in secondary Raynaud\u02bcs phenomenon","volume":"6","author":"Bounameaux","year":"1984","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jbspin.2021.105309_bib0710","article-title":"Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis","author":"Pope","year":"1998","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jbspin.2021.105309_bib0715","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105309_bib0720","doi-asserted-by":"crossref","first-page":"e17266","DOI":"10.1097\/MD.0000000000017266","article-title":"Effects of sarpogrelate hydrochloride on peripheral arterial disease: a meta-analysis of randomized controlled trials","volume":"98","author":"Lu","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jbspin.2021.105309_bib0725","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/147323000002800602","article-title":"Suppressive effect of sarpogrelate hydrochloride on respiratory failure and right ventricular failure with pulmonary hypertension in patients with systemic sclerosis","volume":"28","author":"Kato","year":"2000","journal-title":"J Int Med Res"},{"key":"10.1016\/j.jbspin.2021.105309_bib0730","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1346-8138.2011.01432.x","article-title":"Effects of sarpogrelate hydrochloride on skin ulcers and quality of life in patients with systemic sclerosis","volume":"39","author":"Yoshimasu","year":"2012","journal-title":"J Dermatol"},{"key":"10.1016\/j.jbspin.2021.105309_bib0735","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/03009740410007078","article-title":"Treatment of systemic sclerosis with the 5-HT3 receptor antagonist tropisetron","volume":"33","author":"Stratz","year":"2004","journal-title":"Scand J Rheumatol Suppl"},{"key":"10.1016\/j.jbspin.2021.105309_bib0740","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1067\/mcp.2000.110456","article-title":"Paroxetine decreases platelet serotonin storage and platelet function in human beings","volume":"68","author":"Hergovich","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jbspin.2021.105309_bib0745","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jad.2019.02.063","article-title":"Plasma serotonin levels are associated with antidepressant response to SSRIs","volume":"250","author":"Holck","year":"2019","journal-title":"J Affect Disord"},{"key":"10.1016\/j.jbspin.2021.105309_bib0750","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/rheumatology\/40.9.1038","article-title":"Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine","volume":"40","author":"Coleiro","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2021.105309_bib0755","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00296-006-0254-9","article-title":"Citalopram-induced Raynaud's phenomenon","volume":"27","author":"Peir\u00f3","year":"2007","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jbspin.2021.105309_bib0760","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S0006-3223(97)00188-1","article-title":"Fluoxetine-induced Raynaud's phenomenon","volume":"41","author":"Rudnick","year":"1997","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jbspin.2021.105309_bib0765","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1177\/000331979604700909","article-title":"Digital infarction in a patient with Raynaud's phenomenon associated with treatment with a specific serotonin reuptake inhibitor: a case report","volume":"47","author":"Bell","year":"1996","journal-title":"Angiology"},{"key":"10.1016\/j.jbspin.2021.105309_bib0770","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1345\/aph.18402","article-title":"Raynaud's syndrome in a patient treated with milnacipran","volume":"33","author":"Bourgade","year":"1999","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jbspin.2021.105309_bib0775","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/rheumatology\/keg137","article-title":"Serotonin reuptake inhibitors, Raynaud's phenomenon and erythromelalgia [4]","volume":"42","author":"Rey","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2021.105309_bib0780","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.berh.2016.03.004","article-title":"Connective tissue disease-related pulmonary arterial hypertension","volume":"30","author":"Thakkar","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2021.105309_bib0785","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1517\/14728222.2011.600692","article-title":"Terguride for pulmonary arterial hypertension","volume":"15","author":"Antoniu","year":"2011","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.jbspin.2021.105309_bib0790","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1183\/09059180.00007513","article-title":"Pathogenesis of pulmonary arterial hypertension: lessons from cancer","volume":"22","author":"Guignabert","year":"2013","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jbspin.2021.105309_bib0795","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/15563650.2018.1447119","article-title":"Drug-associated pulmonary arterial hypertension","volume":"56","author":"McGee","year":"2018","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.jbspin.2021.105309_bib0800","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejphar.2018.02.017","article-title":"Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and treprostinil in a monocrotaline-induced pulmonary arterial hypertension rat model","volume":"827","author":"Bhat","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jbspin.2021.105309_bib0805","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1161\/01.RES.0000216858.04599.e1","article-title":"Serotonin inhibits voltage-gated K + currents in pulmonary artery smooth muscle cells","volume":"98","author":"Cogolludo","year":"2006","journal-title":"Circ Res"},{"key":"10.1016\/j.jbspin.2021.105309_bib0810","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-15463-x","article-title":"Remodeling of active endothelial enhancers is associated with aberrant gene-regulatory networks in pulmonary arterial hypertension","volume":"11","author":"Reyes-Palomares","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jbspin.2021.105309_bib0815","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0148657","article-title":"Serotonin 2B receptor antagonism prevents heritable pulmonary arterial hypertension","volume":"11","author":"West","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jbspin.2021.105309_bib0820","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1183\/09031936.00126010","article-title":"Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats","volume":"37","author":"Dumitrascu","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jbspin.2021.105309_bib0825","first-page":"1","article-title":"5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure","volume":"2015","author":"Janssen","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jbspin.2021.105309_bib0830","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.gene.2018.09.020","article-title":"5-HTT, BMPR2, EDN1, ENG, KCNA5 gene polymorphisms and susceptibility to pulmonary arterial hypertension: a meta-analysis","volume":"680","author":"Jiao","year":"2019","journal-title":"Gene"},{"key":"10.1016\/j.jbspin.2021.105309_bib0835","doi-asserted-by":"crossref","DOI":"10.1186\/s11658-020-00237-6","article-title":"Upregulation of miR-361-3p suppresses serotonin-induced proliferation in human pulmonary artery smooth muscle cells by targeting SERT","volume":"25","author":"Zhang","year":"2020","journal-title":"Cell Mol Biol Lett"},{"key":"10.1016\/j.jbspin.2021.105309_bib0840","doi-asserted-by":"crossref","DOI":"10.1177\/2045894020971954","article-title":"Hemodynamic effects of fluoxetine in pulmonary arterial hypertension: an open label pilot study","volume":"10","author":"Sodimu","year":"2020","journal-title":"Pulm Circ"},{"key":"10.1016\/j.jbspin.2021.105309_bib0845","first-page":"A4193","article-title":"Kar5585, a first-in-class oral tryptophan hydroxylase 1 (tph1) inhibitor as a novel candidate for the treatment of pulmonary arterial hypertension","volume":"195","author":"Paralkar","year":"2017","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.jbspin.2021.105309_bib0850","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jbspin.2021.105309_bib0855","first-page":"S17","article-title":"Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis","volume":"30","author":"Daoussis","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2021.105309_bib0860","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2021.105309_bib0865","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","article-title":"A multicenter, open label, comparative study of B cell depletion therapy with rituximab for systemic sclerosis-associated interstitial lung disease","volume":"46","author":"Daoussis","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2021.105309_bib0870","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jbspin.2021.105309_bib0875","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00296-009-0966-8","article-title":"The effects and mechanisms of mycophenolate mofetil on pulmonary arterial hypertension in rats","volume":"30","author":"Yi","year":"2010","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jbspin.2021.105309_bib0880","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1164\/rccm.202009-3481OC","article-title":"Safety and efficacy of B cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary arterial hypertension: a multicenter, double-blind, randomized, placebo-controlled trial","volume":"204","author":"Zamanian","year":"2021","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.jbspin.2021.105309_bib0885","first-page":"105","article-title":"Vascular involvement in systemic sclerosis (scleroderma)","volume":"4","author":"Pattanaik","year":"2011","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.jbspin.2021.105309_bib0890","article-title":"The serotonin receptor 2 inhibitor terguride has beneficial effects on skin fibrosis: results from a phase 2 proof of concept study [abstract]","volume":"68","author":"Distler","year":"2016","journal-title":"Arthritis Rheumatol"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X21001822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X21001822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:28:34Z","timestamp":1761150514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X21001822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":89,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1297319X21001822"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2021.105309","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serotonin and systemic sclerosis. An emerging player in pathogenesis","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2021.105309","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105309"}}